Cited by Colorectal cancer

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer DOI

Christian Rolfo, Philip C. Mack, Giorgio V. Scagliotti

et al.

Journal of Thoracic Oncology, Journal Year: 2021, Volume and Issue: 16(10), P. 1647 - 1662

Published: July 8, 2021

Language: Английский

Citations

446

Clinical management of metastatic colorectal cancer in the era of precision medicine DOI

Fortunato Ciardiello, Davide Ciardiello, Giulia Martini

et al.

CA A Cancer Journal for Clinicians, Journal Year: 2022, Volume and Issue: 72(4), P. 372 - 401

Published: April 26, 2022

Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second most common cause deaths. Initial clinical presentation as metastatic CRC (mCRC) occurs in 20% patients. Moreover, up to 50% patients with localized disease eventually develop metastases. Appropriate management these still a challenging medical issue. Major efforts have been made unveil molecular landscape mCRC. This has resulted identification several druggable tumor targets aim developing personalized treatments for each patient. review summarizes improvements mCRC emerging era precision medicine. In fact, stratification, on which current treatment algorithm based, although it does not completely represent complexity this disease, first significant step toward clinically informative genetic profiling implementing more effective therapeutic approaches. relevant increase control patient survival. The next steps will be integrate comprehensive knowledge gene alterations, microenvironment protein expression profiling, host immune competence well application resulting dynamic changes medicine-based continuum care approach could result individual prognostic predictive parameters, help clinician choosing appropriate program(s) throughout entire journey CA Cancer J Clin. 2022;72:000-000.

Language: Английский

Citations

371

Delivering precision oncology to patients with cancer DOI

Joaquı́n Mateo, Lotte Steuten, Philippe Aftimos

et al.

Nature Medicine, Journal Year: 2022, Volume and Issue: 28(4), P. 658 - 665

Published: April 1, 2022

Language: Английский

Citations

247

Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up DOI

Thierry Conroy, Per Pfeiffer, Valérie Vilgrain

et al.

Annals of Oncology, Journal Year: 2023, Volume and Issue: 34(11), P. 987 - 1002

Published: Sept. 9, 2023

Language: Английский

Citations

198

Precision oncology in metastatic colorectal cancer — from biology to medicine DOI

Federica Di Nicolantonio, Pietro Paolo Vitiello, Silvia Marsoni

et al.

Nature Reviews Clinical Oncology, Journal Year: 2021, Volume and Issue: 18(8), P. 506 - 525

Published: April 16, 2021

Language: Английский

Citations

181

Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study DOI

Changhoon Yoo, Kyu‐pyo Kim, Jae Ho Jeong

et al.

The Lancet Oncology, Journal Year: 2021, Volume and Issue: 22(11), P. 1560 - 1572

Published: Oct. 16, 2021

Language: Английский

Citations

171

The evolving landscape of biomarker testing for non-small cell lung cancer in Europe DOI

Keith M. Kerr,

Fréderic Bibeau,

Erik Thunnissen

et al.

Lung Cancer, Journal Year: 2021, Volume and Issue: 154, P. 161 - 175

Published: Feb. 22, 2021

The discovery of oncogenic driver mutations rendering non-small cell lung cancer (NSCLC) targetable by small-molecule inhibitors, and the development immunotherapies, have revolutionised NSCLC treatment. Today, instead non-selective chemotherapies, all patients with advanced eligible for treatment (and increasing numbers earlier, less extensive disease) require fast comprehensive screening biomarkers first-line patient selection targeted therapy, chemotherapy, or immunotherapy (with without chemotherapy). To avoid unnecessary re-biopsies, biomarker before should also include markers that are actionable from second-line onwards; PD-L1 expression testing is mandatory initiating Population differences exist in frequency mutations: EGFR more frequent Asia than Europe, whereas converse true KRAS mutations. In addition to approved therapies, a number emerging therapies being investigated clinical trials. Guidelines vary country, targets requirement molecular strategies expected increase. meet diagnostic demands, rapid technologies single-driver been implemented. Improvements DNA- RNA-based next-generation sequencing enable analysis group genes one assay; however, turnaround times remain relatively long. Consequently, implemented alongside sequencing. Further challenges evolving landscape primary secondary resistance mechanisms therapies. Therefore, on collected at time disease progression, combination circulating tumour DNA may provide important information guide second- third-line Furthermore, longitudinal can insights into evolution heterogeneity during course disease. We summarise best practice Europe changing diagnosis

Language: Английский

Citations

163

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment DOI

Antonio Passaro, Maise Al Bakir, Emily G. Hamilton

et al.

Cell, Journal Year: 2024, Volume and Issue: 187(7), P. 1617 - 1635

Published: March 1, 2024

Language: Английский

Citations

150

Treatment landscape of metastatic pancreatic cancer DOI

Sara De Dosso,

Alexander Siebenhüner,

Thomas Winder

et al.

Cancer Treatment Reviews, Journal Year: 2021, Volume and Issue: 96, P. 102180 - 102180

Published: March 18, 2021

Language: Английский

Citations

140

EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma DOI

Domenico Alvaro, Gregory J. Gores,

Joël Walicki

et al.

Journal of Hepatology, Journal Year: 2023, Volume and Issue: 79(1), P. 181 - 208

Published: April 20, 2023

Language: Английский

Citations

140